• AstraZeneca won EU clearance for Trixeo Aerosphere as maintenance asthma therapy in patients aged 12 and older uncontrolled on medium-dose ICS/LABA.
• The single-inhaler triple combination adds a LAMA to ICS/LABA; it is marketed as Breztri Aerosphere in the US, China, Japan.
• Approval was backed by Phase III KALOS and LOGOS data showing better lung function, lower severe exacerbation rates versus ICS/LABA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.